Johnson & Johnson to Showcase Global and China Premieres at the Third China International Import Expo

Shanghai, July 30, 2020 /PRNewswire/ -- The countdown to the third China International Import Expo (CIIE) has begun, with preparations in full swing across all sectors. As a "veteran participant" of the CIIE, Johnson & Johnson, a global leader in healthcare, is participating in the expo for the third time and has been elected as a council member of the Exhibitor Alliance. Johnson & Johnson will showcase a range of innovative products and technologies making their debut in China and even globally at its CIIE booth. Meanwhile, the company is making every effort to prepare for the newly launched Public Health and Epidemic Prevention Zone at this year's CIIE, comprehensively demonstrating Johnson & Johnson's positive contributions and outstanding achievements in combating the epidemic, improving human health, and advancing public health development.

Participating in the China International Import Expo (CIIE) for the third time, Johnson & Johnson has expanded its booth space from 500 square meters last year to 800 square meters this year, making it one of the largest exhibitors in the medical device exhibition area. The company will comprehensively and multi-dimensionally showcase a range of innovative products brought by its subsidiaries, as well as its popular star products.

In the medical device sector, Johnson & Johnson will unveil multiple products making their “global debuts” and “China debuts” across orthopedics, surgery, and electrophysiology, including the Harmonic HD1000i ultrasonic scalpel, 3D-printed minimally invasive orthopedic guides, ETHICON VICRYL* Plus antibacterial sutures, and the PulseRider aneurysm neck reconstruction device for bifurcation aneurysms, further demonstrating its leadership in driving healthcare innovation and its steadfast commitment to serving patients in China.

Johnson & Johnson’s eye health business, Johnson & Johnson Vision, will debut a range of cutting-edge technologies and innovative products for the first time at the China International Import Expo. Among them, Acuvue^®Oasys^®Daily disposable toric contact lenses feature an innovative ASD (Accelerated Stabilization Design) and HydraLuxe tear film biomimetic technology, meeting the needs of astigmatic wearers for clear, stable vision and comfort; the new generation of extended depth-of-focus hybrid intraocular lens, TECNIS Synergy™Innovatively combining the advantages of Extended Depth of Focus (EDOF) continuous range-of-vision IOL technology with multifocal IOL technology, it provides continuous vision across the entire visual range—from 33 cm for near vision to distance—enabling patients to see more clearly and comprehensively at every point in their visual range.

In the pharmaceutical sector, Janssen, Johnson & Johnson’s pharmaceutical subsidiary in Xi’an, has benefited from multiple opening-up initiatives implemented by the Chinese government over the past two years. The company has continuously introduced innovative medicines into China and collaborated with the government and various partners to steadily improve access to these innovations. Of the 62 innovative drugs marketed by the company in China, 51 have been included in the National Reimbursement Drug List. This year, Janssen will continue to showcase its portfolio of innovative medicines and introduce new models of pharmaceutical innovation, covering therapeutic areas such as immunology, hematologic oncology, solid tumors, and public health.

In the consumer goods sector, Aveeno, a well-known North American natural skincare brand, along with Neutrogena’s retinol skincare line and Dr. Ci:Labo’s beauty products, have gained widespread popularity among consumers after being showcased at the previous two China International Import Expos (CIIE). This year, Neutrogena will globally debut its new retinol series, specially customized for Chinese consumers, at the CIIE. Listerine will also make its global premiere of the third-generation “Fairy Water,” developed based on consumer insights. In addition, Rogaine, a professional hair regrowth brand from the United States,^®will also enter mainland China via the CIIE platform.

At this year’s CIIE Public Health and Epidemic Prevention Zone, Johnson & Johnson will showcase its relentless efforts to foster innovative collaborations and jointly address public health challenges. These include COVID-19 pandemic control measures such as vaccine development; innovative solutions for public health challenges like tuberculosis and HIV/AIDS prevention and control, aimed at improving access to innovative products; multiple public-welfare partnerships addressing the health needs of women and children; and proactive initiatives to advance global health by establishing platforms for disease prevention and control education, advocating for public health cooperation, and promoting reforms in public health models.

"In the new normal of the post-pandemic era, the China International Import Expo (CIIE) continues to serve as an important window for China to build a dual-circulation development pattern that integrates domestic and international markets. It is also a key platform for all sectors to strengthen economic and trade exchanges and cooperation, promoting mutual benefit and win-win outcomes. 'As a long-time friend of the CIIE, Johnson & Johnson is full of confidence in the development prospects of the Chinese market and the significance of this important platform. Furthermore, China’s continuously improving business environment and policies benefiting enterprises have revealed more new opportunities for growth. In 2020, marking the 35th anniversary of Johnson & Johnson’s entry into China, we are delighted to see the thriving development of China’s healthcare industry, further improvements in public health levels, and a more robust national healthcare security system,' said Song Weiqun, Chairman of Johnson & Johnson China."：“We look forward to seizing new opportunities in the development of the Chinese market by participating in the Third China International Import Expo, telling the Johnson & Johnson China story well, leveraging our core business expertise, introducing more new technologies and products to China, meeting the needs of patients and consumers, and contributing to Healthy China.”

Currently, the Chinese market has become Johnson & Johnson’s fastest-growing market globally and one of the most important markets for the company’s business. Johnson & Johnson attaches great importance to its development in China. In October 2019, the Johnson & Johnson Global Executive Committee announced in Beijing that it would position China as a “Global Innovation Engine,” making it the first Fortune 500 company to strategically deploy the innovative status of the Chinese market. Johnson & Johnson is accelerating the introduction of innovative products and technologies, cultivating local innovation, research and development, and high-end intelligent manufacturing capabilities, building an open innovation ecosystem. Each year, it serves hundreds of millions of patients and consumers in China, and remains committed to innovation-driven growth, promoting the long-term development of China’s healthcare industry, and co-creating a healthier future.

“We have observed that China’s market recovery has been at the forefront globally, whether in containing the epidemic, resuming work and production, safeguarding people’s livelihoods, or driving economic growth. This has significantly bolstered the confidence of foreign-invested enterprises, including Johnson & Johnson, in their long-term development in China,” said Song Weiqun, Chairman of Johnson & Johnson China. “We believe that in the new normal of the post-pandemic era, the Chinese market will further unleash its strong development potential. The public’s pursuit of high-quality healthcare services and the market’s expectation for innovative technologies will continue to position China as a global engine for innovation.” Johnson & Johnson will continue to leverage its role as an industry leader, collaborate with peers, and utilize important platforms such as the China International Import Expo (CIIE) to promote the vigorous development of the healthcare industry and contribute to human health.